---
schema_version: "secwatch.filing_event.v1"
accession: "0001104659-24-130537"
form_type: "8-K"
ticker: "TAOX"
cik: "0001571934"
company_name: "TAO Synergies Inc."
filed_at: "2024-12-20T23:59:59+00:00"
generated_at: "2026-05-29T00:18:06.078117+00:00"
event_type: "other_material"
sentiment: "neutral"
materiality_score: 0.6
calibrated_materiality_score: 0.6
confidence: "high"
source: SEC EDGAR
---

# Synaptogenix forms special committee to explore strategic alternatives; ends Bryostatin-1 MS trial

## Summary
- Board formed special committee to explore strategic opportunities; $19.6M cash and ~1.3M shares outstanding as of Sept 30, 2024.
- Terminated Phase 1 trial of Bryostatin-1 in multiple sclerosis due to slow enrollment.
- CEO Alan Tuchman's base salary reduced to $12,500/month effective Jan 1, 2025.
- President/CSO Daniel Alkon consulting fee reduced to $16,000/month under new agreement.
- Company expects dramatic cash burn decline; submitted NIH grant proposal for Bryostatin-1.

## SEC filing metadata
- accession: 0001104659-24-130537
- form_type: 8-K
- ticker: TAOX
- cik: 0001571934
- company_name: TAO Synergies Inc.
- filed_at: 2024-12-20T23:59:59+00:00
- event_type: other_material
- sentiment: neutral
- materiality_score: 0.6
- calibrated_materiality_score: 0.6
- confidence: high
- sec_items: 5.02, 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1571934/000110465924130537/0001104659-24-130537-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1571934/000110465924130537/tm2431397d1_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001104659-24-130537
- JSON: https://secwatch.observer/filing/0001104659-24-130537.json
- Plain text: https://secwatch.observer/filing/0001104659-24-130537.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.